Experts in hematology/oncology review recent updates in the treatment of multiple myeloma presented at key conferences and share insight on the impact on clinical practice.
EP. 9: Updates From ASH 2021 for Belantamab-based Combinations in Myeloma
February 11th 2022Ola Landgren, MD, PhD, and Joshua Richter, MD, review belantamab mafodotin–based combination regimens currently being evaluated in relapsed/refractory multiple myeloma, as well as the newly diagnosed setting, as presented at the recent ASH 2021 meeting.
EP. 11: Ongoing Trials of Belantamab Mafodotin in MM and Optimal Position in Treatment Landscape
February 18th 2022Joshua Richter, MD, and Sagar Lonial, MD, FACP, review key ongoing clinical trials with belantamab mafodotin in patients with multiple myeloma and the optimal position for belantamab mafodotin in the myeloma treatment landscape.
EP. 12: Treatment Options for Patients Progressing on Belantamab Mafodotin in MM
February 25th 2022Katja Weisel, MD, reviews potential mechanisms of resistance to belantamab mafodotin in patients with multiple myeloma, and Sagar Lonial, MD, FACP, discusses potential treatment options for patients who progress on belantamab mafodotin.